Introduction
Patients and Methods
Catheterization Procedure and Follow-up
Statistical Analysis
Results
Patient Data
Gender | |
Male | 80 (53.7%) |
Female | 69 (46.3%) |
Approach | |
Percutaneous | 142 (95.3%) |
Hybrid | 7 (4.7%) |
Amount of interventions | |
Patients with 1 intervention | 143 (96.0%) |
Patients with 2 interventions | 6 (4.0%) |
Age at implantation* | 6.3 (0.01–66.1) years |
< 1 years | 19 (12.8%) |
1–10 years | 70 (47.0%) |
> 10–20 years | 28 (18.8%) |
> 20 years | 32 (21.5%) |
Height at implantation** | 118 (49–188) cm |
Bodyweight at implantation** | 21 (3.2–117) kg |
VSD Memb | ADO II | VSD Musc | Nit-Occlud | ADO I | Rashkind | |
---|---|---|---|---|---|---|
n = 65 | n = 33 | n = 27 | n = 24 | n = 3 | n = 3 | |
Age at implantation | 11.4 (0.5–65.1) | 2.2 (0–54.9) | 1.9 (0.2–34.5) | 9.4 (0.6–57.7) | 9 (2.-46.8) | 23.8 (12.1–26.9) |
Height in cm | 155 (65–188) | 92 (49–183) | 87 (56–176) | 137.5 (66–185) | 132 (87–184) | / |
Bodyweight in kg | 38 (6.7–117) | 12.5 (3.2–104) | 11 (4.1–64.5) | 32.9 (5.9–87) | 30 (12.1–72) | / |
Device size in mm | 6 (4–16) | 5 (3–6) | 8 (6–16) | 8.5 (4–14) | 8 (6–12) | 15 (12–17) * |
Device Size
Follow-up
VSD Memb | ADO II | VSD Musc | Nit-Occlud | Rashkind | ADO I | |
---|---|---|---|---|---|---|
(n = 65) | (n = 33) | (n = 27) | (n = 24) | (n = 3) | (n = 3) | |
Lost to follow-up | n = 12 (18%) | n = 6 (18%) | n = 7 (26%) | n = 1 (4%) | n = 0 | n = 1 (33%) |
Follow-up > 1 year | n = 48 (74%) | n = 24 (73%) | n = 20 (74%) | n = 21 (88%) | n = 3 (100%) | n = 2 (67%) |
Follow-up < 1 year | n = 5 (8%) | n = 3 (9%) | n = 0 | n = 2 (8%) | n = 0 | n = 0 |
n = 53 | n = 27 | n = 20 | n = 23 | n = 3 | n = 2 | |
---|---|---|---|---|---|---|
Follow-up (years) (median (range)) | 6.5 (0.5–13.1) | 2.8 (0.1–6.3) | 8.3 (1.8–13.4) | 6.2 (0.1–12.8) | 20.1 (15.6–21.3) | 8.4 (5.8–11.1) |
2nd device implantation1 2nd device Residual shunts | 1# ADO II 5 (7.7%) | 2#,* 2 × ADO II 5 (15.2%) | 1# Nit-Occlud 3 (11.1%) | 1# Nit-Occlud 7 (29.2%) | 0 | 0 |
Death | 2 (3.1%) | 1 (3%) | 2 (7.4%) | 0 | 1 (33.3%) | 0 |
cAVB | 1 | 0 | 0 | 0 | 0 | 0 |
Device explantation | 2 | 0 | 0 | 2 | 0 | 0 |